RxSight, Inc. (NASDAQ:RXST – Get Free Report) stock price was up 3.6% on Friday. The company was trading at $47.70 and was last traded at $47.70. About 139,177 shares were traded during the trading day, a decline of 70% from its average daily volume of 461,650 shares. The stock previously closed at $46.04.

Wall Street analysts weigh in

RXST has been the subject of several analyst reports. Needham & Company LLC increased their price target on shares of RxSight from $64.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Wells Fargo & Company increased their price target on RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, May 7th. BTIG Research increased their price target on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Oppenheimer increased their price target on RxSight from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, May 7th. Finally, Stifel Nicolaus lowered their price target on shares of RxSight from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Seven investment analysts have rated the stock with a “buy” rating. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $65.14.

Check out our latest stock report on RXST

RxSight Stock Return

The stock has a market cap of $1.73 billion, a price/earnings ratio of -37.12, and a beta of 1.20. The company has a 50-day moving average price of $57.04 and a 200-day moving average price of $53.25.

RxSight (NASDAQ:RXST – Get Free Report) last released its earnings results on Monday, May 06. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.08). The company had revenue of $29.51 million during the quarter, compared to analysts’ expectations of $27.56 million. RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The company’s quarterly revenue increased by 68.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.42) EPS. On average, analysts expect RxSight, Inc. to post -0.75 earnings per share for the current fiscal year.

Insider buying and selling

In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $52.69, for a total transaction of $526,900.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at $734,393.22. The transaction was disclosed in a document filed with the SEC, which can be accessed at this link . In other news, CEO Ronald M. Md Kurtz sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $60.15, for a total value of $2,406,000.00. Following the transaction, the chief executive officer now owns 764,610 shares of the company’s stock, valued at $45,991,291.50. The sale was disclosed in a document filed with the Securities & Exchange Commission and available for review on the SEC website. Also, CFO Shelley B. Thunen sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 1. The shares were sold at an average price of $52.69, for a total transaction of $526,900.00. Following the sale, the chief financial officer now owns 13,938 shares of the company’s stock, valued at $734,393.22. The disclosure for this sale can be found here. Insiders have sold a total of 75,625 shares of the company’s stock worth $4,425,250 in the last 90 days. 9.36% of the shares are held by company insiders.

Institutional investors weigh in on RxSight

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of RxSight by 21.6% in the third quarter. Vanguard Group Inc. now owns 1,433,953 shares of the company’s stock worth $39,993,000 after acquiring an additional 255,150 shares in the last quarter. Legato Capital Management LLC increased its position in shares of RxSight by 57.2% in the fourth quarter. Legato Capital Management LLC now owns 20,320 shares of the company’s stock worth $819,000 after purchasing an additional 7,395 shares in the last quarter. Arizona State Retirement System bought a new position in shares of RxSight in the fourth quarter worth approximately $261,000. Clarus Group Inc. Bought a new position in shares of RxSight during the fourth quarter worth approximately $202,000. Finally, New York State Common Retirement Fund increased its stake in RxSight by 25.8% in the fourth quarter. New York State Common Retirement Fund now owns 135,438 shares of the company’s stock worth $5,461,000 after acquiring an additional 27,758 shares during the period. Institutional investors own 78.78% of the company’s shares.

About RxSight

(Get free report)

RxSight, Inc., a commercial-stage medical device company, is engaged in the research and development, manufacture and sale of light-adjustable intraocular lenses (LAL) for use in cataract surgery in the United States and internationally. It offers the RxSight System, which enables physicians to adjust and improve patients’ visual acuity following cataract surgery.

Also see

Get daily news and reviews for RxSight – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on RxSight and related companies with MarketBeat.com’s FREE daily email newsletter.